Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec 1;102(48):e36297.
doi: 10.1097/MD.0000000000036297.

A new strategy for the treatment of heavily pretreated metastatic breast cancer: A case report and review of the literature

Ting-Ting Ge  1   2 , Xiao-Juan Pan  1   2 , Xi-Meng Zuo  1 , Xiao-Guang Shi  1 , Yu-Kun Wang  1 , Ping Sun  1 , Xiang Gao  1 , Xue Feng  1 , Shuang Gao  1 , Tang-Shun Wang  1
Affiliations
Review

A new strategy for the treatment of heavily pretreated metastatic breast cancer: A case report and review of the literature

Ting-Ting Ge et al. Medicine (Baltimore). .

Abstract

Background: Breast cancer is one of the most common type of cancers worldwide and remains a critical health issue. Although there are numerous treatment options for advanced metastatic breast cancer, the results are not satisfactory, particularly for triple-negative breast cancer. New treatment modalities need to be explored.

Case presentation: We present the case of a breast cancer patient with multiple metastases who achieved a good response and tolerance to the combination treatment of utidelone plus capecitabine. After being treated with 10 cycles of combined treatment, the patient is now in a good general condition with a progression-free survival time of 10 months.

Conclusion: To our knowledge, this is the first report of utidelone plus capecitabine successfully treating a patient with heavily pretreated metastatic breast cancer. This combined treatment offers a new option for patients with multi-drug resistant breast cancer.

PubMed Disclaimer

Conflict of interest statement

The authors have no funding and conflicts of interest to disclose.

Figures

Figure 1.
Figure 1.
Patient previous treatment timeline and efficacy evaluation.
Figure 2.
Figure 2.
(A) Timeline of left breast tumor changes. Since February 2022, the patient has been receiving a combination treatment of utidelone with capecitabine. There has been a significant reduction in the mass with the progressing treatment cycles. (B) Image changes during combination treatment. The red arrows point to the part of the tumor.
See this image and copyright information in PMC

References

    1. Sung H, Ferlay J, Siegel RL, et al. . Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–49. - PubMed
    1. Xiao L, Hu X, Wang S, et al. . A case report of local recurrence developing 24 years after mastectomy for breast cancer recurrence from breast cancer after 24 Years. Medicine (Baltim). 2016;95:e3807. - PMC - PubMed
    1. Tashima Y, Kawano K. A case of local recurrence developing thirty-nine years after mastectomy for breast cancer. Gan To Kagaku Ryoho. 2014;41:357–9. Japanese. - PubMed
    1. Kusama M, Kaise H, Nakayama S, et al. . A case of postoperative lung and pleural recurrence after 20 years in a breast cancer patient with marked response to orally administered UFT and cyclophosphamide. Gan To Kagaku Ryoho. 2000;27:1573–6. Japanese. - PubMed
    1. Igarashi T, Itoh K, Fujii H, et al. . Successful treatment by radiation and hormone therapy of isolated local recurrence of breast cancer 24 years after mastectomy accompanied by immune thrombocytopenia: a case report. Jpn J Clin Oncol. 1998;28:270–5. - PubMed

MeSH terms